VEGFA and hypertensive disorder: The most common adverse events (AEs; > 35% in either of the treatment arms) were hypertension, diarrhea, hand-foot syndrome (HFS), hair color changes, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), fatigue, decreased appetite, proteinuria, leukopenia, neutropenia, decreased neutrophil count, decreased platelet count, and thrombocytopenia; these AEs were consistent with those commonly observed for the class of VEGF TKI.